Alberto Bardelli Lab

Tumor ‘Age’ in Early-Onset Colorectal Cancer.
Mauri G, Patelli G, Crisafulli G, Siena S, Bardelli A.
Cell. 2025 [In press]

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.
Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, Corti G, Rospo G, Novara L, Mussolin B, Bartolini A, Cam N, Patel R, Yan S, Shoemaker R, Wild R, Di Nicolantonio F, Sartore-Bianchi A, Li G, Siena S, Bardelli A.
Nat Rev Cancer. 2024 Oct;24(10):694-717.

Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells.
Sogari A, Rovera E, Grasso G, Mariella E, Reilly NM, Lamba S, Mauri G, Durinikova E, Vitiello PP, Lorenzato A, Avolio M, Piumatti E, Bonoldi E, Aquilano MC, Arena S, Sartore-Bianchi A, Siena S, Trusolino L, Donalisio M, Russo M, Di Nicolantonio F, Lembo D, Bardelli A.
Cell Rep Med. 2024 Feb 20;5(2):101376.

Precision oncology for KRASG12C-mutant colorectal cancer.
Di Nicolantonio F, Bardelli A.
Nat Rev Clin Oncol. 2023 Jun;20(6):355-356.

Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.
Amodio V, Lamba S, Chilà R, Cattaneo CM, Mussolin B, Corti G, Rospo G, Berrino E, Tripodo C, Pisati F, Bartolini A, Aquilano MC, Marsoni S, Mauri G, Marchiò C, Abrignani S, Di Nicolantonio F, Germano G, Bardelli A.
Cancer Cell. 2023 Jan 9;41(1):196-209.

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, Bartolini A, Fenocchio E, Amatu A, Manca P, Bergamo F, Tosi F, Mauri G, Ambrosini M, Daniel F, Torri V, Vanzulli A, Regge D, Cappello G, Marchiò C, Berrino E, Sapino A, Marsoni S, Siena S, Bardelli A.
Nat Med. 2022 Aug;28(8):1612-1618.